Methods of treating Fabry patients having renal impairment
US11278539B2 · kind B2 · utility
4Cited by
38References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 12, 2021 |
| Grant date | Mar 22, 2022 |
| Priority date | — |
| Expiry date | Aug 12, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/48
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in α-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.